Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $98.9545.

A number of analysts recently commented on the company. Citigroup lifted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday. Finally, Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at $3,671,117.80. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 45,577 shares of company stock worth $3,855,527. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. MV Capital Management Inc. bought a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the first quarter worth $25,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the fourth quarter worth $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. Finally, Hilton Head Capital Partners LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

EW stock opened at $85.72 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a 50 day moving average price of $87.34 and a 200 day moving average price of $83.94. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The stock has a market capitalization of $49.36 billion, a PE ratio of 45.60, a price-to-earnings-growth ratio of 2.20 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.